-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$254.21-5.86% Downside
Recent Analyst Forecasts and Stock Ratings
Alnylam Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. has been rated by research analysts at Canaccord Genuity, Bank of America Securities, BMO Capital, RBC Capital, Goldman Sachs, UBS in the past 90 days.